Sandhoff Disease Pipeline: 5+ Biotech Firms Driving Rare Disease Innovation Through Gene Therapy and Enzyme Replacement | DelveInsight

Sandhoff Disease, a rare and fatal lysosomal storage disorder, is seeing progress through the efforts of over 5 companies, including IntraBio, Sanofi, Polaryx Therapeutics, and Azafaros. The Sandhoff pipeline primarily focuses on gene therapy, substrate reduction, and enzyme replacement therapies aimed at correcting the underlying enzyme deficiency. Despite its ultra-rare prevalence, advancements in AAV-based vectors and CNS-targeted delivery systems are driving a new era of hope for patients and caregivers dealing with this devastating disorder.

DelveInsight's "Sandhoff Disease Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Sandhoff disease market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Sandhoff disease drugs, the Sandhoff disease pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Explore the full pipeline analysis for Sandhoff disease and uncover key opportunities @ https://www.delveinsight.com/report-store/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Sandhoff Disease Pipeline Report
• DelveInsight's Sandhoff disease pipeline analysis depicts a strong landscape with 5+ active players developing 5+ pipeline drugs for Sandhoff Disease treatment.
• The leading Sandhoff disease companies include IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, and others are evaluating their lead assets to improve the Sandhoff disease treatment landscape.
• Key Sandhoff disease pipeline therapies in various stages of development include IB1001, Venglustat, PLX 300, PLX-200, AZ 3102, and others.
• ​In November 2024, McMaster University researchers published a study in Human Molecular Genetics identifying 4-phenylbutyric acid (4-PBA), an FDA-approved drug, as a potential treatment for Sandhoff and Tay-Sachs diseases. The study found that 4-PBA alleviated endoplasmic reticulum stress in spinal cord neurons of a mouse model, leading to improved motor function and extended lifespan. This repurposed drug could offer a new avenue for managing these rare genetic disorders, pending further clinical trials to determine optimal human dosing. ​
• ​In March 2021, UMass Chan Medical School used a novel neurosurgical technique to deliver gene therapy for Tay-Sachs and Sandhoff diseases. The procedure involved convection-enhanced delivery (CED) of AXO-AAV-GM2 directly into the brain and spinal cord, overcoming the blood-brain barrier. This approach, tailored for infants, marked a significant advancement in treating these neurodegenerative disorders.
• ​In November 2020, Axovant Gene Therapies announced that the FDA lifted its clinical hold and cleared the IND application to begin a registrational study of AXO-AAV-GM2 gene therapy for treating Tay-Sachs and Sandhoff diseases.

Request a sample and discover the recent breakthroughs happening in the Sandhoff disease pipeline landscape @ https://www.delveinsight.com/report-store/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sandhoff Disease Overview
Sandhoff disease is a rare and severe lysosomal storage disorder caused by harmful mutations in the HEXB gene, which result in a deficiency of the enzymes beta-hexosaminidase A and B. These enzymes are crucial for breaking down certain lipids within lysosomes, the recycling centers of cells. When they are deficient, lipids accumulate abnormally in nerve cells, leading to progressive damage of the brain and spinal cord (central nervous system). This neurodegeneration impairs both cognitive and motor functions. Sandhoff disease closely resembles Tay-Sachs disease in its symptoms and underlying mechanisms. It is extremely rare, affecting approximately one in a million individuals worldwide.

Find out more about Sandhoff disease medication @ https://www.delveinsight.com/report-store/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sandhoff Disease Treatment Analysis: Drug Profile
IB1001: IntraBio
IB1001 (N-acetyl-L-leucine) is an orally administered modified amino acid that has shown potential in restoring neuronal function and slowing disease progression in neurological circuits. Its mechanism includes altering glucose and antioxidant metabolism, reducing lysosomal storage, and decreasing neuroinflammation in the cerebellum. IntraBio is conducting a Phase II study to assess the safety and efficacy of IB1001 for treating GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease).

Venglustat: Sanofi
Venglustat is a novel oral therapy designed to inhibit the accumulation of abnormal glycosphingolipids (GSLs), which contribute to cell dysfunction and disease progression. It is currently undergoing Phase III trials for the treatment of Sandhoff Disease.

Learn more about the novel and emerging Sandhoff disease pipeline therapies @ https://www.delveinsight.com/report-store/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Sandhoff Disease Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Sandhoff Disease Pipeline Report
• Coverage: Global
• Key Sandhoff Disease Companies: IntraBio, Sanofi, Polaryx Therapeutics, Azafaros, and others.
• Key Sandhoff Disease Pipeline Therapies: IB1001, Venglustat, PLX 300, PLX-200, AZ 3102, and others.

Dive deep into rich insights for drugs used for Sandhoff disease treatment; visit @ https://www.delveinsight.com/report-store/sandhoff-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Sandhoff Disease Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Sandhoff Disease Pipeline Therapeutics
6. Sandhoff Disease Pipeline: Late-Stage Products (Phase III)
7. Sandhoff Disease Pipeline: Mid-Stage Products (Phase II)
8. Sandhoff Disease Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.